trial

A Safety，Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule

NCTId NCT05233657
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Unknown
Enrollment 58 (estimated)
Sponsored by Zhejiang Jingxin Pharmaceutical Co., Ltd.
Primary completion 2022-01-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Unknown
Enrollment
58 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2020-01-04
Primary completion
2022-01-31
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
JX11502MA

Sponsors

Zhejiang Jingxin Pharmaceutical Co., Ltd.Lead Sponsor

Sites

1 total
Shanghai, China

Facts & assertions

4 sourced
Enrollment
58
Phase
PHASE1
Primary Completion Date
2022-01-31
Status
UNKNOWN
relationships
The graph out of here
drug
JX11502MA
drug
lead_sponsor
Zhejiang Jingxin Pharmaceutical Co., Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication